| Literature DB >> 21873040 |
V Valayannopoulos1, A Brassier, A Chabli, C Caillaud, M Lemoine, T Odent, J B Arnoux, P de Lonlay.
Abstract
In the last years, much progress has been achieved in the treatment of lysosomal storage disorders. Until recently only symptomatic treatment was available for the affected patients. Progressively enzyme replacement treatments have been developed for several diseases, namely Gaucher disease, Fabry disease, mucopolysaccharidoses type I, II and VI and Pompe disease. In this review we will summarize the efficacy and safety of these treatments and describe new therapeutic trials for other lysosomal storage disorders or perspectives in the use of currently available treatments.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21873040 DOI: 10.1016/j.arcped.2011.07.002
Source DB: PubMed Journal: Arch Pediatr ISSN: 0929-693X Impact factor: 1.180